• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

111年的变应原免疫疗法:这是过敏性疾病中唯一可用的疾病改良疗法漫长且成功的历史。

111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases.

作者信息

Gutermuth Jan, Grosber Martine, Pfaar Oliver, Bergmann Karl Christian, Ring Johannes

机构信息

Department of Dermatology, University Hospital Free University Brussels, Brussels, Belgium.

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg.

出版信息

Allergol Select. 2022 Nov 21;6:248-258. doi: 10.5414/ALX02330E. eCollection 2022.

DOI:10.5414/ALX02330E
PMID:36457720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9707371/
Abstract

The great milestones in medicine almost always have their precursors, which help the great event to break through. So it was with allergen-specific immunotherapy (AIT) and the great work of Noon and Freeman and their world-renowned publication in 1911. In this article, we want to outline AIT's long journey, from early attempts to achieve tolerance to allergens in the environment. Many very different methods were used; from homeopathy to the use of recombinant allergens. Initially, the allergen extracts were given only subcutaneously, but then also through other routes, such as nasal, rectal, intradermal, epicutaneous, in lymph nodes, or oral. It was the great merit of Bill Franklin, whom many of us still experienced as active participants in congresses, to point out that the effect of AIT must be documented not only by clinical observation but in a controlled form including placebo injections. AIT was thus transferred to evidence-based medicine, which we successfully apply today. We would like to express our gratitude to Bill Franklin himself and all others involved in the development of AIT with this summary of 111 years of immunotherapy.

摘要

医学上的重大里程碑几乎总是有其先驱者,他们助力这一伟大事件取得突破。过敏原特异性免疫疗法(AIT)以及努恩和弗里曼的伟大成就及其1911年举世闻名的出版物便是如此。在本文中,我们想概述AIT漫长的发展历程,从早期在环境中实现对过敏原耐受的尝试说起。人们采用了许多截然不同的方法,从顺势疗法到使用重组过敏原。最初,过敏原提取物仅通过皮下注射给药,但后来也通过其他途径给药,如鼻腔、直肠、皮内、经皮、淋巴结内或口服。比尔·富兰克林的伟大功绩在于,我们许多人仍能在大会上看到他作为积极参与者的身影,他指出AIT的效果不仅必须通过临床观察来记录,还应以包括安慰剂注射在内的对照形式来记录。于是,AIT被引入了循证医学,而我们如今成功地应用着这一医学模式。通过对111年免疫疗法的总结,我们要向比尔·富兰克林本人以及所有参与AIT发展的其他人表达我们的感激之情。

相似文献

1
111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases.111年的变应原免疫疗法:这是过敏性疾病中唯一可用的疾病改良疗法漫长且成功的历史。
Allergol Select. 2022 Nov 21;6:248-258. doi: 10.5414/ALX02330E. eCollection 2022.
2
Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.欧洲和美国变应原免疫疗法流派之间的折中:来自墨西哥免疫疗法指南制定小组(GUIMIT)的讨论
World Allergy Organ J. 2020 Aug 21;13(8):100444. doi: 10.1016/j.waojou.2020.100444. eCollection 2020 Aug.
3
Allergen immunotherapy in allergic rhinitis: current use and future trends.变应性鼻炎的变应原免疫治疗:当前应用与未来趋势。
Expert Rev Clin Immunol. 2017 Sep;13(9):897-906. doi: 10.1080/1744666X.2017.1333423. Epub 2017 Jun 15.
4
Immunological effects of adjuvanted low-dose allergoid allergen-specific immunotherapy in experimental murine house dust mite allergy.低剂量变应原免疫原性过敏原特异性免疫疗法对实验性屋尘螨变应性的免疫作用。
Allergy. 2022 Mar;77(3):907-919. doi: 10.1111/all.15012. Epub 2021 Jul 26.
5
Allergen immunotherapy in people, dogs, cats and horses - differences, similarities and research needs.人与犬、猫、马过敏原免疫治疗的差异、相似性及研究需求。
Allergy. 2018 Oct;73(10):1989-1999. doi: 10.1111/all.13464. Epub 2018 May 27.
6
Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.实验变应原免疫治疗方法:过敏性哮喘小鼠模型中的皮下和舌下脱敏。
Methods Mol Biol. 2021;2223:295-335. doi: 10.1007/978-1-0716-1001-5_20.
7
Allergens and Adjuvants in Allergen Immunotherapy for Immune Activation, Tolerance, and Resilience.变应原和佐剂在免疫激活、免疫耐受和免疫弹性中的变应原免疫治疗作用。
J Allergy Clin Immunol Pract. 2021 May;9(5):1780-1789. doi: 10.1016/j.jaip.2020.12.008. Epub 2021 Mar 19.
8
Allergen-Specific Immunotherapies for Food Allergy.食物过敏的变应原特异性免疫疗法
Allergy Asthma Immunol Res. 2018 May;10(3):189-206. doi: 10.4168/aair.2018.10.3.189.
9
AIT: New Avenues in Allergen Immunotherapy.AIT:变应原免疫治疗的新途径。
Handb Exp Pharmacol. 2022;268:135-149. doi: 10.1007/164_2021_514.
10
Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy.变应性免疫疗法与药物疗法的药物经济学
Expert Rev Clin Immunol. 2021 Mar;17(3):255-268. doi: 10.1080/1744666X.2021.1886079. Epub 2021 Feb 28.

引用本文的文献

1
House dust mite sublingual allergen immunotherapy tablet is safe and well-tolerated in Dutch clinical practice.屋尘螨舌下变应原免疫治疗片剂在荷兰临床实践中安全且耐受性良好。
Front Allergy. 2024 Feb 29;5:1355324. doi: 10.3389/falgy.2024.1355324. eCollection 2024.
2
Canine Atopic Dermatitis: Prevalence, Impact, and Management Strategies.犬特应性皮炎:患病率、影响及管理策略
Vet Med (Auckl). 2024 Feb 13;15:15-29. doi: 10.2147/VMRR.S412570. eCollection 2024.
3
The long-term efficacy of intra-cervical lymphatic immunotherapy on adults with allergic rhinitis: A randomized controlled study.

本文引用的文献

1
Allergen immunotherapy during the COVID-19 pandemic-A survey of the German Society for Allergy and Clinical Immunology.2019冠状病毒病大流行期间的变应原免疫治疗——德国变态反应和临床免疫学会的一项调查
Clin Transl Allergy. 2022 Mar;12(3):e12134. doi: 10.1002/clt2.12134.
2
Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis.变应原免疫治疗和/或生物制剂治疗 IgE 介导的食物过敏:系统评价和荟萃分析。
Allergy. 2022 Jun;77(6):1852-1862. doi: 10.1111/all.15211. Epub 2022 Jan 19.
3
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence.
宫颈内淋巴免疫疗法对成人过敏性鼻炎的长期疗效:一项随机对照研究。
Clin Transl Allergy. 2024 Feb;14(2):e12341. doi: 10.1002/clt2.12341.
4
A high-dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio.一种用于皮下变应原免疫疗法的高剂量、脱色素聚合桦树花粉提取物具有良好的疗效/安全性比。
Clin Transl Allergy. 2023 Nov;13(11):e12315. doi: 10.1002/clt2.12315.
5
Clinical outcomes of AIT in the elderly population.老年人群中 AIT 的临床结局。
Curr Opin Allergy Clin Immunol. 2023 Aug 1;23(4):341-345. doi: 10.1097/ACI.0000000000000925. Epub 2023 Jun 19.
变应原免疫治疗的百年历程:从经验观察到循证医学。
Allergy. 2022 Feb;77(2):454-468. doi: 10.1111/all.15023. Epub 2021 Sep 27.
4
Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA LEN consensus.从过敏性鼻炎和普通感冒鉴别 COVID-19 症状和体征:ARIA-EAACI-GA LEN 共识。
Allergy. 2021 Aug;76(8):2354-2366. doi: 10.1111/all.14815. Epub 2021 May 14.
5
COVID-19 pandemic and allergen immunotherapy-an EAACI survey.COVID-19 大流行与变应原免疫治疗:一项 EAACI 调查。
Allergy. 2021 Nov;76(11):3504-3516. doi: 10.1111/all.14793. Epub 2021 Aug 25.
6
[Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)].[新型冠状病毒肺炎大流行期间变应原免疫治疗的处理:ARIA-EAACI-AeDA-GPA-DGAKI立场文件(袖珍指南)]
Laryngorhinootologie. 2020 Oct;99(10):676-679. doi: 10.1055/a-1170-8426. Epub 2020 Aug 21.
7
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.AR101 口服免疫治疗欧洲花生过敏儿童的疗效和安全性(ARTEMIS):一项多中心、双盲、随机、安慰剂对照 3 期试验。
Lancet Child Adolesc Health. 2020 Oct;4(10):728-739. doi: 10.1016/S2352-4642(20)30234-0. Epub 2020 Jul 20.
8
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).ARIA-EAACI关于哮喘与2019冠状病毒病的声明(2020年6月2日)
Allergy. 2021 Mar;76(3):689-697. doi: 10.1111/all.14471. Epub 2020 Sep 21.
9
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.COVID-19 大流行:关于组织过敏诊所的实用注意事项——一项 EAACI/ARIA 立场文件。
Allergy. 2021 Mar;76(3):648-676. doi: 10.1111/all.14453.
10
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.应对 COVID-19 大流行期间的变应原免疫治疗:ARIA-EAACI 立场声明。
Allergy. 2020 Jul;75(7):1546-1554. doi: 10.1111/all.14336.